Superior Planning, LLC’s Neuropace NPCE Stock Holding History

Superior Planning, LLC’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14	Buy	+1	New	+$15	﹤0.01%	2135

Other funds holding NPCE

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Legato Capital Management San Francisco, California $1.11B AUM 60.78% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Superior Planning, LLC's NPCE Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Neuropace (NPCE) in Q3 2026: 1 share worth $14. The stake represents ﹤0.01% of the portfolio and ranks #2135 among its holdings.

47 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

Superior Planning, LLC held 1 share of Neuropace worth $14 as of Q3 2026.
Neuropace was a new Superior Planning, LLC position in Q3 2026.
Neuropace made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2135 holding.
47 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.